Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC

HighTower Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,534,627 shares of the biopharmaceutical company’s stock after buying an additional 84,450 shares during the quarter. HighTower Advisors LLC owned 0.12% of Gilead Sciences worth $193,885,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. California State Teachers Retirement System grew its holdings in shares of Gilead Sciences by 12,498.3% during the 2nd quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company’s stock valued at $30,469,248,000 after acquiring an additional 239,254,365 shares in the last quarter. BlackRock Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth about $15,393,785,000. State Street Corp increased its position in Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.0%

Shares of GILD opened at $150.99 on Monday. The stock’s 50-day moving average price is $136.67 and its 200 day moving average price is $136.39. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $2.01 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GILD shares. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Rothschild & Co Redburn decreased their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Finally, Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares in the company, valued at $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 105,000 shares of company stock valued at $14,495,820. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.